Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Failure analysis of bolts in deluge valve bonnet in cooling tower system in petrochemical plant.

Scientific reports·2025
Same author

Influence of airborne particle abrasion on dentin bonding effectiveness of a 2-step universal adhesive.

Journal of dentistry·2024
Same author

Bonding performance of experimental HEMA-free two-step universal adhesives to low C-factor flat dentin.

Dental materials : official publication of the Academy of Dental Materials·2023
Same author

Overcoming the blood brain barrier in glioblastoma: Status and future perspective.

Revue neurologique·2023
Same author

Acrylamide monomers in universal adhesives.

Dental materials : official publication of the Academy of Dental Materials·2023
Same author

Multiparameter evaluation of acrylamide HEMA alternative monomers in 2-step adhesives.

Dental materials : official publication of the Academy of Dental Materials·2020

Related Experiment Video

Updated: Jun 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.

M H Ahmed1, C D Byrne

  • 1Chemical Pathology Department, Southampton University Hospitals NHS Trust, Southampton, UK.

Diabetes, Obesity & Metabolism
|October 1, 2010
PubMed
Summary
This summary is machine-generated.

Ezetimibe effectively lowers LDL cholesterol by inhibiting intestinal absorption. However, trials show it does not impact atherosclerosis progression, suggesting further research into its benefits for other conditions like insulin resistance and NAFLD is needed.

Related Experiment Videos

Last Updated: Jun 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • Ezetimibe is a cholesterol absorption inhibitor targeting Niemann-Pick C1 Like1 (NPC1L1) in the small intestine.
  • It effectively reduces low-density lipoprotein cholesterol (LDL-C).
  • Recent trials like ARBITER 6-HALTS and ENHANCE indicated no effect on atherosclerosis despite significant LDL-C reduction.

Purpose of the Study:

  • To review the efficacy of ezetimibe in managing cardiovascular disease (CVD) risk factors.
  • To explore potential therapeutic benefits of ezetimibe beyond LDL-C reduction.
  • To highlight emerging research on ezetimibe for insulin resistance, non-alcoholic fatty liver disease (NAFLD), gallstones, and dyslipidemia in chronic renal failure and post-transplant patients.

Main Methods:

  • Literature review of clinical trials and recent studies on ezetimibe.
  • Analysis of data from ARBITER 6-HALTS and ENHANCE trials.
  • Synthesis of findings regarding ezetimibe's impact on atherosclerosis and other metabolic conditions.

Main Results:

  • Ezetimibe significantly decreases LDL-C levels.
  • ARBITER 6-HALTS and ENHANCE trials demonstrated no impact of ezetimibe on atherosclerosis progression.
  • Emerging evidence suggests potential benefits in insulin resistance, NAFLD, gallstones, and dyslipidemia associated with chronic kidney disease and organ transplantation.

Conclusions:

  • Ezetimibe's role in atherosclerosis requires further investigation despite its LDL-C lowering capacity.
  • Ezetimibe shows promise for managing metabolic conditions linked to increased cardiovascular risk.
  • Additional research is warranted to fully assess ezetimibe's therapeutic potential in these diverse clinical areas.